Clinical Trials Browser

Phase 1/2 × Ovarian Neoplasms × veliparib × Clear all

NCT01012817 2025-09-15

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase 1/2 Active not recruiting

88 enrolled 23 charts

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT01690598 2015-06-10

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Phase 1/2 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms